Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022

SELL
$0.56 - $1.0 $41,322 - $73,790
-73,790 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$0.9 - $8.39 $7,693 - $71,717
-8,548 Reduced 10.38%
73,790 $67,000
Q4 2021

Feb 09, 2022

BUY
$6.58 - $8.44 $541,784 - $694,932
82,338 New
82,338 $660,000
Q2 2021

Aug 11, 2021

SELL
$5.75 - $7.59 $521,605 - $688,519
-90,714 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$4.14 - $9.22 $4,769 - $10,621
1,152 Added 1.29%
90,714 $600,000
Q4 2020

Feb 03, 2021

BUY
$3.58 - $4.85 $91,701 - $124,232
25,615 Added 40.06%
89,562 $376,000
Q3 2020

Nov 04, 2020

SELL
$4.79 - $6.3 $20,209 - $26,579
-4,219 Reduced 6.19%
63,947 $306,000
Q2 2020

Aug 05, 2020

BUY
$4.5 - $6.53 $306,747 - $445,123
68,166 New
68,166 $414,000
Q4 2019

Feb 07, 2020

SELL
$5.84 - $10.51 $452,477 - $814,304
-77,479 Closed
0 $0
Q3 2019

Nov 04, 2019

SELL
$5.76 - $9.44 $22,296 - $36,542
-3,871 Reduced 4.76%
77,479 $446,000
Q2 2019

Aug 07, 2019

BUY
$9.1 - $15.55 $740,285 - $1.26 Million
81,350 New
81,350 $740,000

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $157M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.